Features & Analyses

  • Fang Qi and Danlei Wu of Fangda Partners discuss what information qualifies for trade secrets protection including the scope of trade secrets, protective measures in place for trade secrets and confidentiality of trade secrets with reference to judicial decisions taking a lead role in the development of trade secrets law

    September 17, 2021
  • Daisy Duan of King & Wood Mallesons discusses enterprises that will qualify to be an applicant under the simplified procedure for unilateral advance pricing arrangements (APAs) and those that are excluded, and the benefits of having a streamlined APA process for MNCs in cross-border transactions

    September 10, 2021
  • Casper Sek of Jin Mao Partners highlights the requirements of the Regulations on CII Protection from the perspective of compliance practices for companies operating in China and discusses what is a critical information infrastructure and critical information infrastructure operator, the regulators involved and compliance under the new regulations

    September 03, 2021
  • Edward Tung, legal counsel for Hong Kong-based venture capital firm ORI Capital, discusses the growing importance of ESG, the rise of special purpose acquisition companies (SPACs) and the advantage of having scientific expertise when representing healthcare and biotechnology companies.

    August 20, 2021
  • Ting Wu of Haiwen & Partners raises some questions to highlight how China's newly implemented drug patent linkage system attempts to resolve drug patent disputes in the early stages, which will have a sweeping impact on market entry strategies for chemical drugs in China

    August 13, 2021
  • Andrew Sim and Alanna Rennie of Baker McKenzie discuss the key provisions of the new Judicial Interpretation on plant variety rights (PVR), which will encourage more consistent rulings by the people's court and grant stronger judicial protection to PVR holders in China

    July 22, 2021